Literature DB >> 3580706

Evaluation of a new and potent cholecystokinin antagonist on motor responses of the guinea-pig intestine.

L Barthó, P Holzer, F Lembeck, I T Lippe, I Setnikar.   

Abstract

The potency and selectivity of D,L-4-(3,4-dichloro-benzoyl-amino)-5-(dipentyl-amino)-5-oxo-pen tan oic acid (CR 1409) as a cholecystokinin (CCK) antagonist was investigated on motor responses of the longitudinal and circular muscles of the guinea-pig isolated ileum. CR 1409 was further used to examine whether nerve-mediated motor responses to electrical field stimulation or distension of the gut wall may involve the release of CCK-like peptides. CR 1409 (0.06-2.1 microM) antagonized longitudinal muscle responses to ceruletide (caerulein, a CCK-related decapeptide) in a concentration dependent and competitive manner (pA2 7.77); responses to CCK-octapeptide (CCK-8) were antagonized with a similar potency. Contractions of the circular muscle evoked by ceruletide were also blocked by CR 1409 (0.2-0.4 microM). Longitudinal muscle contractions in response to dimethylphenylpiperazinium, bethanechol, histamine, substance P, or 5-hydroxytryptamine (5-HT), and circular muscle contractions evoked by acetylcholine, 5-HT, substance P, or substance K were not altered by CR 1409 (0.4 microM). Longitudinal muscle contractions induced by electrical field stimulation (with pulses delivered at 0.05 and 1 Hz in the absence, and at 5 Hz in the presence of atropine) were not or only slightly reduced by CR 1409 (0.4 microM). Longitudinal contractions due to activation of extrinsic nerves by capsaicin remained unaltered in the presence of CR 1409 (0.4 microM). Reflex contractions of the circular muscle, induced by balloon distension and recorded orally to the site of distension, and peristaltic activity elicited by intraluminal infusion of Tyrode solution remained unaffected by CR 1409 (0.4 microM). 5 These findings indicate that CR 1409 is a potent and selective antagonist of CCK-like peptides in the guinea-pig ileum. The results do not provide any evidence that CCK-like peptides, released from extrinsic or intrinsic neurones, are involved in nerve-mediated contractions of intestinal muscle and in the peristaltic reflex.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3580706      PMCID: PMC1917212          DOI: 10.1111/j.1476-5381.1987.tb11229.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  38 in total

1.  Release of cholecystokinin-immunoreactivity into the vascular bed of the guinea-pig small intestine during peristalsis.

Authors:  J Donnerer; D K Meyer; P Holzer; F Lembeck
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-01       Impact factor: 3.000

2.  New type of nerve-mediated cholinergic contractions of the guinea-pig small intestine and its selective blockade by capsaicin.

Authors:  J Szolcsányi; L Barthó
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-10       Impact factor: 3.000

3.  Effect of neuropeptides on the efficiency of the peristaltic reflex.

Authors:  P Holzer; F Lembeck
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-07       Impact factor: 3.000

4.  Substance P enteric neurons mediate non-cholinergic transmission to the circular muscle of the guinea-pig intestine.

Authors:  M Costa; J B Furness; C O Pullin; J Bornstein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-02       Impact factor: 3.000

5.  Neuronal cholecystokinin, gastrin-releasing peptide, neurotensin, and beta-endorphin in the intestine of the guinea pig. Distribution and possible motor functions.

Authors:  S Leander; R Ekman; R Uddman; F Sundler; R Håkanson
Journal:  Cell Tissue Res       Date:  1984       Impact factor: 5.249

6.  Does cholecystokinin-like immunoreactivity in rat primary sensory neurons represent calcitonin gene-related peptide?

Authors:  G Ju; T Hökfelt; J A Fischer; P Frey; J F Rehfeld; G J Dockray
Journal:  Neurosci Lett       Date:  1986-08-04       Impact factor: 3.046

7.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

8.  Evidence that the action of cholecystokinin octapeptide on the guinea pig ileum longitudinal muscle is mediated in part by substance P release from the myenteric plexus.

Authors:  J B Hutchison; G J Dockray
Journal:  Eur J Pharmacol       Date:  1981-01-05       Impact factor: 4.432

9.  Localization and molecular heterogeneity of cholecystokinin in the central and peripheral nervous system.

Authors:  L I Larsson; J F Rehfeld
Journal:  Brain Res       Date:  1979-04-13       Impact factor: 3.252

10.  Neuropeptides in the gut: quantification and characterization of cholecystokinin octapeptide-, bombesin- and vasoactive intestinal polypeptide-like immunoreactivities in the myenteric plexus of the guinea-pig small institute.

Authors:  J B Hutchison; R Dimaline; G J Dockray
Journal:  Peptides       Date:  1981       Impact factor: 3.750

View more
  5 in total

1.  Effect of a new potent CCK antagonist, lorglumide, on caerulein- and bombesin-induced pancreatic secretion and growth in the rat.

Authors:  C Scarpignato; G Varga; I Dobronyi; M Papp
Journal:  Br J Pharmacol       Date:  1989-03       Impact factor: 8.739

2.  Studies of three non-peptide cholecystokinin antagonists (devazepide, lorglumide and loxiglumide) in human isolated alimentary muscle and guinea-pig ileum.

Authors:  M D'Amato; I F Stamford; A Bennett
Journal:  Br J Pharmacol       Date:  1991-02       Impact factor: 8.739

3.  Physiological role of cholecystokinin on postprandial insulin secretion and gastric meal emptying in man. Studies with the cholecystokinin receptor antagonist loxiglumide.

Authors:  M Fried; W Schwizer; C Beglinger; U Keller; J B Jansen; C B Lamers
Journal:  Diabetologia       Date:  1991-10       Impact factor: 10.122

4.  Reduction of food intake by central administration of cholecystokinin octapeptide in the rat is dependent upon inhibition of brain peptidases.

Authors:  T Griesbacher; G E Leighton; R G Hill; J Hughes
Journal:  Br J Pharmacol       Date:  1989-01       Impact factor: 8.739

5.  Cholecystokinin-2/gastrin antagonists: 5-hydroxy-5-aryl-pyrrol-2-ones as anti-inflammatory analgesics for the treatment of inflammatory bowel disease.

Authors:  E Lattmann; J Sattayasai; R Narayanan; N Ngoc; D Burrell; P N Balaram; T Palizdar; P Lattmann
Journal:  Medchemcomm       Date:  2017-02-17       Impact factor: 3.597

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.